🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

254 results for “AstraZeneca” Clear

  1. IMFINZI 50 mg/mL concentrate for solution for infusion., BEVACIZUMAB, IMJUDO 20 mg/ml concentrate for solution for infusion.

    AstraZeneca AB

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  2. IMFINZI 50 mg/mL concentrate for solution for infusion., Ceralasertib, Inflectra 100 mg powder for concentrate for solution for infusion, Mycophenolate Mofetil 250 mg Capsules

    AstraZeneca AB

    Unresectable or Advanced Melanoma

    phase 2 small molecule active

    1 trial

  3. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.

    AstraZeneca AB

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  4. IMFINZI 50 mg/mL concentrate for solution for infusion., INFLIXIMAB, Lynparza 100 mg film-coated tablets, MYCOPHENOLATE MOFETIL, Lynparza 150 mg film-coated tablets

    AstraZeneca AB

    BRCA Mutations and Early Stage HER2-Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  5. INFLIXIMAB, DS-8201a, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, PERTUZUMAB

    AstraZeneca AB

    HER2-positive Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  6. INFLIXIMAB, FOLINIC ACID, IRINOTECAN HYDROCHLORIDE TRIHYDRATE, CALCIUM FOLINATE, MYCOPHENOLATE MOFETIL, volrustomig, FLUOROURACIL, BEVACIZUMAB

    AstraZeneca AB

    ​​Colorectal cancer​

    phase 2 small molecule active

    1 trial

  7. Inflectra 100 mg powder for concentrate for solution for infusion, Inflectra 100 mg powder for concentrate for solution for infusion, AZD0171, Oleclumab, Mycophenolate Mofetil 250 mg Capsules, Inflectra 100 mg powder for concentrate for solution for infusion, CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion., volrustomig, CISPLATIN , Monalizumab, Datopotamab deruxtecan, Inflectra 100 mg powder for concentrate for solution for infusion, Rilvegostomig, Inflectra 100 mg powder for concentra

    AstraZeneca AB

    Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  8. Lynparza 150 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Stage IV Non Small Cell Lung Cancer whose tumors lack EGFR mutations and ALK fusions

    phase 2 small molecule active

    1 trial

  9. MYCOPHENOLATE MOFETIL, Rilvegostomig, RAMUCIRUMAB, INFLIXIMAB

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. OXALIPLATIN, AZD0901, CAPECITABINE, FLUOROURACIL, AZD7789, volrustomig, CAPECITABINE, CALCIUM FOLINATE, Rilvegostomig

    AstraZeneca AB

    Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  11. OXALIPLATIN, CISPLATIN, OXALIPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., PEMBROLIZUMAB, CAPECITABINE, TRASTUZUMAB, OXALIPLATIN, Rilvegostomig, CAPECITABINE, FLUOROURACIL, volrustomig, DS-8201a

    AstraZeneca AB

    Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressing gastric, GEJ and esophageal cancer

    phase 2 small molecule active

    1 trial

  12. Oleclumab, INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., Datopotamab deruxtecan, PACLITAXEL, Capivasertib, DS-8201a

    AstraZeneca AB

    First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.

    phase 2 small molecule active

    1 trial

  13. PACLITAXEL, MYCOPHENOLATE MOFETIL, volrustomig, INFLIXIMAB, FLUOROURACIL, CISPLATIN

    AstraZeneca AB

    Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherapy), Sub-study 4: Esophageal Squamous Cell Carcinoma (Volrustomig in Combination with Chemotherapy).

    phase 2 small molecule active

    1 trial

  14. PALBOCICLIB, Zoladex 3,6 mg implante en jeringa precargada, AZD8421, PALBOCICLIB, AZD8421, PALBOCICLIB, PALBOCICLIB, RIBOCICLIB, Camizestrant, PALBOCICLIB, ABEMACICLIB, PALBOCICLIB, ABEMACICLIB, AZD8421, ABEMACICLIB

    AstraZeneca AB

    Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)

    phase 2 small molecule active

    1 trial

  15. PARACETAMOL, DIPHENHYDRAMINE, INFLIXIMAB, TOCILIZUMAB, AZD7789, EPINEPHRINE

    AstraZeneca AB

    Relapsed/Refractory Classical Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  16. POMALIDOMIDE , ELRANATAMAB, AZD0305, ELRANATAMAB

    AstraZeneca AB

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  17. Placebo for AZD2693 Solution for Injection, Placebo for AZD2693 Solution for Injection

    AstraZeneca AB

    Non-cirrhotic non-alcoholic steatohepatitis with fibrosis

    phase 2 small molecule active

    1 trial

  18. Placebo for AZD4144, AZD4144

    AstraZeneca AB

    Sepsis-associated acute kidney injury (AKI)

    phase 2 small molecule active

    1 trial

  19. Placebo for AZD5148, AZD5148

    AstraZeneca AB

    Recurrence of Clostridioides difficile Infection

    phase 2 small molecule active

    1 trial

  20. RITUXIMAB, CYCLOPHOSPHAMIDE , AZD0486, PREDNISOLONE , VINCRISTINE , Calquence 100 mg film-coated tablets, RITUXIMAB , AZD0486, DOXORUBICIN , Calquence 100 mg film-coated tablets, PREDNISONE , AZD0486, AZD0486

    AstraZeneca AB

    Mantle Cell Lymphoma, Large B-Cell Lymphoma, Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma

    phase 2 small molecule active

    1 trial

  21. Rilvegostomig, Rilvegostomig

    AstraZeneca AB

    Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, stage III unresectable Non-small Cell Lung Cancer (Protocol Parts A-B), stage IV Non-small Cell Lung Cancer (Protocol Parts A-E).

    phase 2 small molecule active

    1 trial

  22. SELUMETINIB, SELUMETINIB, Selumetinib, Selumetinib

    AstraZeneca AB

    Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)

    phase 2 small molecule active

    1 trial

  23. Saruparib

    AstraZeneca AB

    Advanced/Recurrent Ovarian cancer

    phase 2 small molecule active

    1 trial

  24. Saruparib, Camizestrant, Datopotamab deruxtecan, PACLITAXEL , Saruparib, DS-8201a, Saruparib, Saruparib

    AstraZeneca AB

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources